1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. Europe Biosimilars Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. Europe Biosimilars Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1 Rising demand for biosimilars due to cost-effectiveness
- 5.1.2 Expanding use of biosimilars in oncology and immunology
5.2 Market Opportunities
- 5.2.1 Adoption of biosimilars to lower healthcare costs
- 5.2.2 Expansion into emerging markets with biosimilar drugs
5.3 Future Trends
- 5.3.1 Growing adoption of biosimilars
- 5.3.2 Support for biosimilar approvals
5.4 Impact of Drivers and Restraints
6. Europe Biosimilars Market Regional Analysis
6.1 Europe Biosimilars Market Overview
6.2 Europe Biosimilars Market Revenue 2020-2030 (US$ Million)
6.3 Europe Biosimilars Market Forecast Analysis
7. Europe Biosimilars Market Analysis – by Disease Indication
7.1 Cancer
- 7.1.1 Overview
- 7.1.2 Cancer: Europe Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Diabetes
- 7.2.1 Overview
- 7.2.2 Diabetes: Europe Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Autoimmune Disease
- 7.3.1 Overview
- 7.3.2 Autoimmune Disease: Europe Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Other Disease Indication
- 7.4.1 Overview
- 7.4.2 Other Disease Indication: Europe Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)
8. Europe Biosimilars Market Analysis – by Route of Administration
8.1 Intravenous
- 8.1.1 Overview
- 8.1.2 Intravenous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
8.2 Subcutaneous
- 8.2.1 Overview
- 8.2.2 Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
9. Europe Biosimilars Market Analysis – by Drug Class
9.1 Granulocyte Colony-Stimulating Factor
- 9.1.1 Overview
- 9.1.2 Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
9.2 Insulin
- 9.2.1 Overview
- 9.2.2 Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
9.3 TNF Blockers and Monoclonal Antibodies
- 9.3.1 Overview
- 9.3.2 Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10. Europe Biosimilars Market – Europe Analysis
10.1 Europe
- 10.1.1 Europe Biosimilars Market Breakdown, by Key
Country, 2023 and 2030 (%)
- 10.1.1.1 Europe Biosimilars Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 UK:
Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.1.1 UK: Europe Biosimilars Market Breakdown, by Disease Indication
- 10.1.1.1.2 UK: Europe Biosimilars Market Breakdown, by Route of Administration
- 10.1.1.1.3 UK: Europe Biosimilars Market Breakdown, by Drug Class
- 10.1.1.2 Germany:
Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.2.1 Germany: Europe Biosimilars Market Breakdown, by Disease Indication
- 10.1.1.2.2 Germany: Europe Biosimilars Market Breakdown, by Route of Administration
- 10.1.1.2.3 Germany: Europe Biosimilars Market Breakdown, by Drug Class
- 10.1.1.3 France:
Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.3.1 France: Europe Biosimilars Market Breakdown, by Disease Indication
- 10.1.1.3.2 France: Europe Biosimilars Market Breakdown, by Route of Administration
- 10.1.1.3.3 France: Europe Biosimilars Market Breakdown, by Drug Class
- 10.1.1.4 Russia:
Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.4.1 Russia: Europe Biosimilars Market Breakdown, by Disease Indication
- 10.1.1.4.2 Russia: Europe Biosimilars Market Breakdown, by Route of Administration
- 10.1.1.4.3 Russia: Europe Biosimilars Market Breakdown, by Drug Class
- 10.1.1.5 Italy:
Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.5.1 Italy: Europe Biosimilars Market Breakdown, by Disease Indication
- 10.1.1.5.2 Italy: Europe Biosimilars Market Breakdown, by Route of Administration
- 10.1.1.5.3 Italy: Europe Biosimilars Market Breakdown, by Drug Class
- 10.1.1.6 Rest of Europe:
Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.6.1 Rest of Europe: Europe Biosimilars Market Breakdown, by Disease Indication
- 10.1.1.6.2 Rest of Europe: Europe Biosimilars Market Breakdown, by Route of Administration
- 10.1.1.6.3 Rest of Europe: Europe Biosimilars Market Breakdown, by Drug Class
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Europe Biosimilars Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 Amgen Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Celltrion Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Sanofi SA
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Biocon Ltd,
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Samsung Bioepis Co Ltd
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Elli Lilly and Co
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Sandoz AG
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Teva Pharmaceitical Industries Ltd
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Pfizer Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Dr. Reddy's Laboratories Ltd
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
Get Free Sample For Europe Biosimilars Market
